Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Add To Watchlist

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > ONCY pelareorep + bispecific antibodies in pancreatic cancer

View:

Post by Noteable on Apr 28, 2022 1:25pm

ONCY pelareorep + bispecific antibodies in pancreatic cancer

April 20, 2022 - The combination of reovirus and CD3-bsAb therapy may become a novel strategy for PC patients.

https://cancerci.biomedcentral.com/articles/10.1186/s12935-022-02583-1

226

Comment

Comment by askretka on Apr 28, 2022 2:47pm

Yes Bispecific antibodies hold great promise going forward. The researchers doing work at in Netherlands is pretty interesting. Hoping for an update on their work. ------------------------------ Researchers at the Leiden University Medical Center (LUMC) in the Netherlands are exploring how to use oncolytic viruses to increase the effectiveness of immunotherapy cancer. ----------------------------- ...more

221

Comment

Comment by Noteable on Apr 28, 2022 5:21pm

Despite a strong initial immunity, treatment with the CD3 bsAb as a monotherapy does not install protective memory responses, however when combined with ONCY's oncolytic virus pelareorep, pelareorep stimulates both the innate and adaptive immune systems which leads to the protective memory response unable to be achieved with CD3 bsAb treatment alone.

196

Comment

Oncolytics Biotech Inc